Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera

Natalia Kruglova, Andrei Siniavin, Vladimir Gushchin and Dmitriy Mazurov

Abstract: The COVID-19 pandemic caused by SARS-CoV-2 has posed a global threat to human lives and economics. One of the best ways to determine protection against the infection is to quantify the neutralizing activity of serum antibodies. Multiple assays have been developed to validate SARS-CoV-2 neutralization; most of them utilized lentiviral or vesicular stomatitis virus-based particles pseudotyped with the spike (S) protein, making them safe and acceptable to work with in many labs. However, these systems are only capable of measuring infection with purified particles. This study has developed a pseudoviral assay with replication-dependent reporter vectors that can accurately quantify the level of infection directly from the virus producing cell to the permissive target cell. Comparative analysis of cell-free and cell-to-cell infection revealed that the neutralizing activity of convalescent sera was more than tenfold lower in cell cocultures than in the cell-free mode of infection. As the pseudoviral system could not properly model the mechanisms of SARS-CoV-2 transmission, similar experiments were performed with replication-competent coronavirus, which detected nearly complete SARS-CoV-2 cell-to-cell infection resistance to neutralization by convalescent sera. These findings suggest that the cell-to-cell mode of SARS-CoV-2 transmission, for which the mechanisms are largely unknown, could be of great importance for treatment and prevention of COVID-19.

Keywords: SARS-CoV-2; cell-to-cell infection; serum neutralization; intron-containing reporter

1. Introduction

SARS-CoV-2 is a respiratory virus, a causative agent of COVID-19. The primary target of the virus is the airway epithelium of the upper respiratory tract [1–3]. During the course of the disease, the virus can descend to the lower respiratory tract, infecting bronchial epithelium and type II pneumocytes [4]. The main receptor for SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2) [1,5,6], determines the viral tropism, which is not restricted to the respiratory epithelium and in certain cases can infect enterocytes, as well as kidney, heart, brain, and other cell types [7,8]. Molecules other than ACE2 have been reported to be involved in SARS-CoV-2 entry, such as neuropilin-1 [9,10], AXL [11], and CD147, although the role of the latter is speculative [12,13].

SARS-CoV-2 entry is mediated by the spike (S) protein [14]. The S protein belongs to trimeric class I fusion proteins [15] that undergo substantial conformational changes when bound to a cellular receptor, leading to fusion between viral and cell membranes [16,17]. The extracellular portion of the spike consists of two subunits: S1 binds to ACE2 and S2 mediates the viral fusion [17]. A newly synthesized spike exists in a metastable prefusion state [17]. Following attachment to permissive cells, the receptor-binding domain (RBD) in the S1 subunit transitions between the inactive ‘down’ position and the accessible ‘up’ position for interaction with ACE2 [18–20]. Using single-molecule fluorescence resonance
energy transfer, Li et al. [21] revealed that, indeed, S protein conformation is dynamic and can be differently stabilized after binding with ACE2 or neutralizing antibodies. However, binding the S protein to ACE2 is not sufficient for triggering membrane fusion, because the fusion peptides of coronavirus S proteins have a ‘hidden’ localization inside the S2 subunit [17]. Proteolytic cleavage at the S2’ site releases fusion peptide. This process is mediated by several host proteases: TMPRSS2, and lysosomal cathepsins B and L [6,22]. Depending on localization within the target cells, these proteases largely determine virus entry sites; plasma membrane in the case of TMPRSS2 or endosomes when cathepsins are engaged [14,23]. In this regard, SARS-CoV-2 is not unique and demonstrates features that have long been known from other coronaviruses [22]. In contrast to the S2’ site, the furin cleavage site at the S1/S2 boundary is a special feature of SARS-CoV-2 that generally distinguishes it from other beta-coronaviruses, such as SARS-CoV [24], with the exception of MERS-CoV, where it is present [22].

An invaluable instrument for coronavirus entry inhibitor assessment is pseudoviruses (PVs). They are safe, reliable, and fast for generating quantitative data relative to fully competent viruses, which often require strict regulation when working with them. The SARS-CoV-2 spike protein is sufficient to mediate pseudovirus entry and many pseudoviral systems were developed during the COVID-19 pandemic, generally using human immunodeficiency virus (HIV) [6,25–29], murine leukemia virus (MLV) [2,30,31], or vesicular stomatitis virus (VSV) [3,5,32,33] platforms. In comparison to retro- or lentiviral particles, which require 48 h to obtain infectivity results, results for VSV-based particles can be obtained within 24 h of infection and at higher titers, although the production is more labor-intensive [6,34,35]. In general, the choice of pseudoviral system is primarily dictated by the preferences of a particular research group [36]. Using pseudoviral tests, large amounts of data on the inhibitory activity of sera from convalescent and vaccinated individuals, monoclonal antibodies, proteins, peptides, and small molecules were collected and analyzed [26–30,37].

Despite fast progress in SARS-CoV-2 entry inhibitor evaluation using PVs, the vast majority of developed systems are capable of measuring infectivity only with purified particles. Below, this is referred to as cell-free infection, meaning no virus-producing cells were added directly to permissive target cells. Meanwhile, the largely unknown—and potentially important—mechanism of SARS-CoV-2 spread from cell-to-cell has not been evaluated with PVs. This study describes the S protein pseudotyped lentiviral system for measuring SARS-CoV-2 infection in both cell-free and cell-to-cell infection settings. This was achieved with replication-dependent reporter vectors that were developed earlier [38,39]. The key feature of these vectors is that the reporter is silent in the PV-producing cells, but active after infection of the target cells and completion of one cycle of viral replication. This enables infectious events to be measured directly in cocultures of producer and target cells at zero background level. The concept was effectuated by placing a reporter cassette in reverse orientation relative to HIV-1 genomic RNA and through interrupting it with an intron, that prevented a functional reporter protein expression from LTR and CMV promoters in transfected (producer) cells. Comparative analysis of SARS-CoV-2 infection in two transmission settings revealed a substantially lower capacity of convalescent sera to neutralize infection in cell cocultures than in a cell-free test. This effect was reproduced with replication-competent SARS-CoV-2, indicating that cell-to-cell transmission of SARS-CoV-2 and its elevated resistance to entry inhibitors are important parameters for monitoring anti-viral immunity and developing anti-coronaviral drugs.

2. Materials and Methods

2.1. Cell Lines

The human embryonic kidney 293T cells were obtained through NIH AIDS Research and Reference Reagent Program. Vero E6 cells were obtained from ATCC (CRL-1586). All cell lines were cultured in high glucose Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich, St. Louis, MO, USA) with sodium pyruvate, sodium bicarbonate, 10% fetal
calf serum (FCS), 2 mM glutamine, and 40 µg/ml gentamicin at 37 °C and 5% CO₂. The cells tested negative for mycoplasma contamination.

2.2. Human Serum Samples

All serum samples were derived from the human serum biobank of the Gamaleya Center for Epidemiology and Microbiology. Study was approved by the local ethics committee of the Moscow First Infectious Disease Hospital (Protocol #2 dated 22 January 2021).

2.3. Plasmid Construction

The plasmid pCG1-SARS-2-S coding for the codon-optimized S-protein was kindly provided by Prof. Dr. Stefan Pöhlmann (Infection Biology Unit of the German Primate Center, Leibniz Institute for Primate Research). C-terminal truncation of the S-protein (ΔC19), addition of 8 amino acids from the HIV gp41 (H2), and mutation of the furin cleavage site PRRA→A (ΔF) were introduced by PCR with Pfu polymerase (Sibenzyme, Russia) and verified by sequencing. The HIV-1 (strain NL4-3) packaging plasmids pCMV-dR8-2 (# 12263) and vector pCMV-VSV-G for expression of the protein G from vesicular stomatitis virus (# 8454) were obtained from Addgene; reporter plasmids pUCHR-inLuc-mR and pUCHR-IR-GFP were described previously [38,39]. The plasmid pUCHR-hACE2 was generated by subcloning the ACE2 coding sequence from the pCG1-hACE2 plasmid obtained from Prof. Dr. Stefan Pöhlmann (Infection Biology Unit of the German Primate Center, Leibniz Institute for Primate Research) into lentiviral vector pUCHR.

2.4. Establishing 293T/ACE2 Target Cell Line

To produce lentiviral particles, 0.35 × 10⁶ 293T cells were plated in 1 well of a 6-well plate in 2.5 mL of growth medium. The next day, the cells were transfected with 0.66 µg of pCMV-dR8-2, 0.88 µg of pUCHR-hACE2, and 0.22 µg pCMV-VSVG using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instruction. At 48 h post transfection, supernatants with PVs were cleared through 0.45 µm pore size filters and used for transduction. 293T cells (8 × 10⁴ per well) were plated in a 24-well plate overnight in 500 µL of growth medium. Serially diluted lentiviral particles were added to the cells, and the percentage of ACE2-positive cells was analyzed by flow cytometry at 48 h post infection. The sample with an approximately 30% level of transduction was selected for further isolation using a Sony MA900 (Sony Biotechnology, San Jose, CA, USA) cell sorter. The cells were expanded and sorted once again to enrich the ACE2-positive population more than 98%.

2.5. Generation of SARS-CoV-2 Pseudotyped Viral Particles

2.5 × 10⁶ 293T cells were plated in a 10 cm dish in 10 mL of growth medium. The next day, the cells were transfected with 5 µg pCMV-dR8-2, 6.67 µg pUCHR-inLuc-mR or pUCHR-IR-GFP, and 3.33 µg of the S-protein coding plasmid using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instruction. At 48 h post transfection, PVs were cleared through 0.45 µm filters, concentrated by centrifugation at 20,000 g, 4 °C, 2.5 h, aliquoted, and stored at −80 °C. PVs were titrated on 293T/ACE2 cells and assessed by flow cytometry (GFP) or by luciferase assay (inLuc). p24 level for each preparation was measured by the HIV-1 p24 ELISA Kit (Vector-Best, Novosibirsk, Russia).

2.6. One-Step Transfection/Infection Assay

A single-round transfection/infection test was performed in a 24-well format. A total of 8 × 10⁴ 293T/ACE2 cells per well plated in 500 µL of growth medium 24 h in advance were transfected with 0.217 µg of pCMV-dR8-2, 0.288 µg of pUCHR-inLuc-mR, and 0.144 µg of wild type or mutant pCG1-SARS-2-S, or 0.072 µg of pCMV-VSVG using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instruction. Then, 48 h post transfection, culture supernatants were harvested, centrifuged, and used for p24 calculation by ELISA. The cells were lysed with the GLO lysis buffer (# E2661, Promega,
Madison, WI, USA), and luciferase activity was determined by the Bright-Glo™ Luciferase Assay System (# E2620, Promega) using GloMax®20/20 Luminometer (Promega).

2.7. Detection of Syncytia Formation

A total of $8 \times 10^4$ 293T cells per well were plated in a 24-well plate in 500 µL of growth medium. After 24 h, the cells were transfected with 0.5 µg pCMV-GFPt and 0.3 µg pCG1-SARS-2-S, pCG1-SARS-2-SAC19, or pCG1-SARS-2-SAC19-H2 using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instruction. The next day, the transfected cells and 293T/ACE2 cells were detached with 1 mM EDTA, mixed at the ratio of 1:1, and plated in wells of a 24-well plate with the total number of $10^5$ cells per well. Images of live cells were acquired by the Nikon eclipse Ti microscope at the x10 magnification 24 h later.

2.8. Single-Cycle Cell-Free Infection

A total of $8 \times 10^4$ 293T/ACE2 cells per well were plated in a 24-well plate in 400 µL of growth medium. The following day, the whole volume was replaced with 400 µL of medium containing PVs. Infection level was determined 48 h later by luciferase assay or flow cytometry. To measure neutralizing activity of sera from COVID-19 patients, sera were serially four-fold diluted in growth medium and preincubated with PVs in the total volume of 400 µL for 1 h at room temperature before addition to target cells.

2.9. Single-Cycle Cell Coculture Infection

To generate pseudovirus-producing cells, $9 \times 10^5$ 293T cells were plated in a 6-cm dish in 5 mL of growth medium. The next day, the cells were transfected with 1.67 µg pCMV-dR8-2, 2.22 µg pUCHR-inLuc-mR, and 1.11 µg pCG1-SARS-2-SdFdC19 using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instruction. Then, 24 h post transfection, producer cells were detached with 1 mM EDTA and washed twice with PBS. A total of $2.6 \times 10^4$ cells were mixed with serial four-fold dilutions of sera in the total volume of 200 µL and incubated for 1 h at 4 °C. Next, they were mixed with $5.4 \times 10^4$ target 293T/ACE2 cells detached with 1 mM EDTA and resuspended in 200 µL of medium. Cell mixture was plated in a 24-well plate and cocultured in the 400 µL volume of medium. Luciferase activity was determined 48 h later.

2.10. SARS-CoV-2 Virus Stock

SARS-CoV-2 strain hCoV-19/Russia/Moscow_PMVL-4 (EPI_ISL_470898) [40] was amplified and titrated on Vero E6 cells. Viral titers were determined as TCID$_{50}$ by endpoint dilution assay. All experiments with live SARS-CoV-2 were performed in a biosafety level 3 facility (BSL-3).

2.11. Cell-Free SARS-CoV-2 Spreading Assay

Vero E6 cells were plated at $8 \times 10^4$ cells/well into 96-well plates the day prior to experiments. Serum samples were serially four-fold diluted in growth medium, mixed with MOI 0.01 of SARS-CoV-2 and incubated for 1 h at 37 °C. The mixture was then added to Vero E6 cells and incubated for 5 days at 37 °C. Cytopathic effect (CPE) was determined by MTT assay [41,42].

2.12. Cell-to-Cell SARS-CoV-2 Spreading Assay

Vero E6 cells were plated into a T25 cell culture flask and infected with SARS-CoV-2 at MOI 0.01. The next day, infected cells were detached with trypsin/EDTA solution (Gibco, USA), washed twice with PBS, mixed with serial four-fold dilutions of sera at $2.6 \times 10^4$ cells per sample, and incubated for 1 h at 37 °C. The mixture was then combined with $5.4 \times 10^4$ uninfected Vero E6 cells in 96-well plates in the total volume of 200 µL and incubated for 5 days at 37 °C. CPE was determined by MTT assay.
2.13. Flow Cytometry

To measure S protein expression on the surface of 293T PV-producing cells, $3 \times 10^5$ transfected cells were incubated with the serum from a convalescent donor at the 1:100 dilution in PSB for 30 min followed by the incubation with the secondary anti-human IgG antibodies conjugated with PE (1:250, # H10104, Thermo Fisher Scientific) for 30 min. ACE2 expression was assessed by staining cells with polyclonal rabbit antibodies against human ACE2 (PAB886Hu01, Cloud-Clone Corp, Katy, TX, USA) followed by secondary anti-rabbit antibodies conjugated to PE (1:250, # P-2771MP, Thermo Fisher Scientific). Samples were analyzed on a CytoFLEX S flow cytometer (Beckman Coulter, Brea, CA, USA). FlowJo LLC software (Ashland, OR, USA) was used for histogram visualization.

2.14. Data Analysis

The data were analyzed and visualized using GraphPad Prism 8 Software (San Diego, CA, USA). NT$_{50}$ values were calculated using a nonlinear regression curve fit to normalized data expressed as % inhibition of infection.

3. Results

3.1. Generation and Optimization of a SARS-CoV-2 Pseudoviral System to Measure Cell-Free Infection

Pseudoviruses are viruses enveloped with a heterologous surface protein that changes their natural tropism. Unlike native systems, heterologous protein envelopes are often incorporated into PV particles at lower efficiency. A number of studies have been focused on optimizing lenti- and retroviral systems pseudotyped with the SARS-CoV S protein. Giroglou et al. showed that C-terminal truncation of the S protein increased retroviral particle titers, explained by the removal of the ER retention signal and exposure of the S protein to the cell surface [43]. Moore et al. found that both C-terminal truncation and substitution of the cytoplasmic portion of the S protein with eight amino acids from the C-terminus of HIV-1 gp41 increased the level of infectious lentiviral particle production [44]. Later on, the spike protein from SARS-CoV-2 with a cytoplasmic portion deleted was used in a number of pseudoviral test systems [6,33,45–47]. The furin cleavage site that was present in SARS-CoV-2 S but not in the SARS-CoV S protein is thought to be involved in spike maturation, virus entry, and syncytium formation [5] and, therefore, can also affect infectivity measured with PVs.

In order to establish an HIV-based infection system, the SARS-CoV-2 S protein was modified by deleting the last 19 amino acids ($\Delta C19$) or substituting them with eight amino acids from HIV-1 gp41 (H2). These modifications were either combined with the mutation in the furin cleavage site RRAR to A ($\Delta F$), or left uncombined, to generate the six variants of spike protein indicated in Figure 1A. Next, a SARS-CoV-2 permissive HEK 293T cell line was established with a stable expression of the human ACE2 receptor via lentiviral transduction and FACS sorting (Figure 1B). A cell-free infectivity assay was set up, as schematically illustrated in Figure 1C. PVs were generated by co-transfecting 293T cells with one of the S-protein-coding plasmids, HIV-1 packaging vector pCMV-dR8-2, and an improved intron-regulated reporter vector pUCHR-inLuc-mR, capable of measuring both cell-free and cell coculture infections using the mean of luciferase activity [38,39]. Additionally, the pUCHR-IR-GFP reporter plasmid without an intron was used to evaluate cell-free infectivity levels using flow cytometry. At 48 h post transfection, supernatants containing PVs were harvested and concentrated by centrifugation. Equal amounts of PVs were added to 293T/ACE2 cells for 48 h, and levels of infection were estimated by measuring luciferase activity or percentage of GFP-positive cells, depending on reporter type. The resulting values of infection were normalized to p24 levels, and presented relative to the values obtained for the wild-type S protein. As shown in Figure 1D, $\Delta C19$ moderately increased the level of infection, while the $\Delta F$ modification had no or little effect on infectivity. By contrast, the $\Delta F$ mutation resulted in about a 1.5 log increase in PV infectivity. On $\Delta F$ background, however, the improving effect of $\Delta C19$ was much less pronounced than...
detected without ∆F. PV titration was used to confirm a substantial effect of the ∆F mutation on the level of PV transduction (~20-fold enhancement in many PV dilutions) (Figure 1E,F). The increased infectivity of the ∆F mutant PVs was not accompanied by an increase in S protein expression on PV-producing 293T cells (Figure 1G). Thus, it was unclear whether ∆F infectivity was enhanced from S incorporation into PVs or if this was a feature of the 293T cellular system, in which S processing by furin is important during the fusion step of the viral life cycle.

In summary, a SARS-CoV-2 cell-free infection test was developed in a 24-well plate format with a high level of sensitivity. Using the ∆F∆C19 modification of the SARS-CoV-2 S protein, 50–60% GFP transduction and about 4 logs over the background elevation of luciferase activity was achieved, making consecutive inhibitory analysis accurate and reproducible.

Figure 1. Development of a SARS-CoV-2 cell-free infection test with PVs. (A) A schematic illustration for S-protein variants used in pseudovirus infection tests. Six different constructs of the S protein were generated by PCR mutagenesis. (B) Evaluation of the ACE2 surface expression on 293T cells stably transduced with the hACE2 using flow cytometry. (C) Experimental setup for SARS-CoV-2 cell-free infection measurement. (D) The levels of infection detected with different variants of the S protein. PVs were added to 293T/ACE2 cells in an equal amount based on HIV-1 Gag quantification. The luciferase activity measured for a mutant spike was normalized to that obtained for the wild-type S protein. Two independent experiments with two different PV preparations were performed. (E,F) The levels of cell-free infection with indicated PVs were measured using either GFP (E) or inLuc (F) reporter. (G) The levels of S protein expression on PV-producing cells estimated by flow cytometry. To express indicated variants of protein S, 293T cells were transfected and stained with convalescent human serum in 48 h. Median fluorescence intensity (MFI) level was calculated for every mutant in the gate of transfected cells and normalized to the MFI detected for wild-type S protein.
3.2. Development of a SARS-CoV-2 Pseudoviral System to Quantify Cell-to-Cell Infection

In order to evaluate SARS-CoV-2 cell-to-cell infection, a one-step transfection–infection assay was set up [38,39]. Briefly, 293T/ACE2 cells were co-transfected with viral vectors, as outlined above, for cell-free infection. In approximately 12–16 h, transfected cells started to produce PVs, which infected nearby 293T/ACE2 cells. At 48 h post transfection, one cycle of replication was complete and luciferase activity could be measured (Figure 2A). Using this assay, the levels of infection with one of the six variants of the S protein were quantified. Wild-type, ΔC19, and H2 proteins did not mediate infection at all; however, all three variants bearing the ΔF mutation supported a good level of infection. The addition of ΔC19 to ΔF increased the level of infectivity by 0.5 log, while the H2 modification had no effect on the signal (Figure 2B). We have previously demonstrated that intron-regulated reporter vectors do not detect infection in cell syncytia, as the reporter protein can be expressed only in actively replicating target cells [38]. Therefore, the ability of differently modified S protein variants to induce syncytia formation in 293T/ACE2 cells was examined. Consistent with previously reported data [6,23,37], a massive cell-cell fusion upon expression of all three variants of spike bearing the furin cleavage site was detected, and there was no syncytia formation in the samples transfected with ΔF variants (Figure 2C). This suggests that S-mediated syncytia formation inhibits lentiviral reporter expression in permissive cells; consequently, wild-type S protein cannot be used to assess cell-to-cell infection in the 293T/ACE2 cellular model. In summary, the possibility of measuring SARS-CoV-2 cell-to-cell infection using the intron-regulated luciferase vector was demonstrated, and the ΔFΔC19 mutant of S was selected for further study.

**Figure 2.** Establishing PV system for measurement of SARS-CoV-2 cell coculture infection. (A) A schematic representation of SARS-CoV-2 one-step transfection–infection assay in 293T/ACE2. (B) The levels of infectivity measured using one-step assay with different spike protein mutants. Samples with the intact furin cleavage site produced no signal above background (n/d). The differences between ΔF mutants were calculated by one-way ANOVA with Tukey’s multiple comparison test, and were significant at $p = 0.0008$ (***). Symbols and color codes in (B) are the same as in Figure 1D,G. (C) Syncytia formation induced by wild-type or mutant SARS-CoV-2 S protein. 293T cells were co-transfected with GFP-expression plasmid and one of the indicated variant of S protein bearing intact furin cleavage site. At 24 h post transfection, cells were detached with 1 mM EDTA and mixed with 293T/ACE2 cells at a 1:1 ratio for another 24 h. Typical images of cells captured on epifluorescence microscope with filters set for FITC are demonstrated (Scale bar, 10 μm).
3.3. Comparative Analysis of the Neutralizing Activity of Convalescent Sera in SARS-CoV-2 Cell-Free and Cell Coculture Pseudoviral Infection Tests

Using the developed pseudoviral infection tests, side-by-side comparisons of the neutralizing activity of convalescent sera from COVID-19 patients in cell-free and cell coculture modes of infection were performed. To avoid possible biases that can be observed when a neutralizing agent is added at the time of infection initiation, neutralization tests were designed to allow either PVs or producer cells to be preincubated with a serum for 1 h prior to the target cell addition (see schematic in Figure 3A). Specifically, cell-free PVs in the amount of 10 ng of p24 were incubated with indicated serum dilutions in a total volume of 400 µL of culture medium, and added to $8 \times 10^4$ 293T/ACE2 cells, seeded overnight in a 24-well plate. The levels of cell-free infection were estimated 48 h later by measuring luciferase activity in cell lysates. In these experimental settings, the results with control samples were consistently reproduced at the level of $\sim 10^6$ RLU, giving an opportunity to detect a wide range of inhibitory activity. Five COVID-19 convalescent sera with high neutralizing activity were selected and evaluated in the cell-free infection test with ∆F∆C19. As shown in Figure 3A,E, all samples demonstrated NT$_{50}$ in a range between 1/1500 and 1/12000 dilution, whereas a non-immune serum had no inhibitory activity. Additionally, in order to determine whether the furin cleavage site mutation or C-terminal truncation influenced neutralization titer, wild-type and ∆C19 variants per se were tested. The inhibition rates against Swt and ∆C19 were similar. The addition of ∆F to ∆C19 moderately reduced serum neutralization capacity in comparison to inhibitory titers measured for wt or ∆C19 S proteins (Figure 3B), including NT$_{50}$ values (Figure 3C). Thus, the ∆F modification in the S protein slightly changed the level of PV neutralization in the cell-free test, but was absolutely necessary for measuring cell coculture infectivity and making the correct comparison between two types of infection.

The cell-to-cell neutralization test was designed to be as similar as possible to settings used for the cell-free PV inhibition analysis. To generate SARS-CoV-2 producer cells, non-permissive 293T cells were co-transfected with pCMV-∆8.2R, pUCHR-inLuc-mR, and pCG1-SARS-2-S∆F∆C19 plasmids, as described for cell-free infection. After 24 h, cells were gently suspended using ethylenediaminetetraacetic acid (EDTA) and washed once with phosphate-buffered saline (PBS); $2.6 \times 10^4$ transfected cells in 200 µL culture medium were preincubated with a certain serum dilution for 1 h at +4 °C and mixed with $5.6 \times 10^4$ 293T/ACE2 cells, giving a total of $8 \times 10^4$ cells in 0.4 mL of culture medium. The cell mixture was placed in the wells of a 24-well plate and incubated for 48 h before luciferase activity measurement (Figure 3D, schematic). The described format, and the resulting ratio of one producer cell to two target cells, provided the optimal sensitivity for measuring cell coculture infection and comparing it to cell-free infection in control samples. As shown in Figure 3D on the right, inhibition of SARS-CoV-2 cell coculture infection required high concentrations of convalescent sera, with NT$_{50}$ detected within the 1/100 to 1/1100 dilution range. Compared to the serum activities against cell-free infection, the neutralization capacities of the same sera against cell coculture infection were more than tenfold lower (Figure 3E). Nonetheless, NT$_{50}$ titers of individual serum samples measured in cell-free and cell-to-cell infection tests correlated with each other (Figure 3F), i.e., sera with a higher inhibitory titer detected in the cell-free infection test more effectively inhibited cell coculture infection.

In summary, by using the developed pseudoviral single-cycle replication assay with the intron-regulated reporter vector, it was demonstrated that SARS-CoV-2 cell coculture infection was much more resistant to neutralization by convalescent sera than infection with purified PVs.
In summary, by using the developed pseudoviral single-cycle replication assay with the intron-regulated reporter vector, it was demonstrated that SARS-CoV-2 cell coculture infection was much more resistant to neutralization by convalescent sera than infection with purified PVs.

Figure 3. Neutralization activity of convalescent sera determined using SARS-CoV-2 PVs. (A) The experimental steps designed for the cell-free neutralization test. Viral particles pseudotyped with ΔFΔC19 were preincubated with human serum dilution for 1 h and added to the 293T/ACE2 target cells. The control RLU values obtained without serum were set at 100%. The levels of infection detected in the presence of immune or non-immune serum were presented relative to control. (B) Neutralizing activity of convalescent sera against wild-type and two indicated S protein mutants measured in a cell-free infection test. The assay was set up as in (A). (C) Correlations between 50% serum-neutralizing titers (NT$_{50}$) calculated for SΔFΔC19-PVs, SΔC19-PVs, and Swt-PVs. (D) A schematic illustrating cell coculture neutralization assay setup (on the left) and neutralization curves (on the right) obtained for indicated sera in this test. 293T cells transfected with viral vectors for 24 h were detached with 1 mM EDTA, incubated with a serially diluted serum for 1 h, and cocultured with 293T/ACE2 cells at 1:2 ratio for 48h. Data were collected and presented as in (A). The average results from three independent experiments ± standard deviations are shown in (A,D). (E) Comparison of the 50% serum-neutralizing titers (NT$_{50}$) obtained in cell-free and cell coculture infection tests with PVs. The values were extracted from data presented in (A,D). (F) The correlation between cell-free and cell coculture neutralizing titers detected for five convalescent sera.
3.4. Neutralization Potential of Convalescent Sera against Replication-Competent SARS-CoV-2

Neutralization tests with PVs, although safe, have serious limitations, since they can only mimic the entry step of the viral life cycle. The mechanisms of viral assembly, egress, and transmission for HIV and coronaviruses are very different, so the HIV-1 core proteins responsible for these processes—and used in this study’s pseudoviral tests—cannot model SARS-CoV-2 cell-to-cell transmission. With an understanding of all the drawbacks of the developed tests, an investigation of whether the resistance of cell-to-cell transmission to antibody neutralization could be reproduced with a full replication-competent SARS-CoV-2 was conducted. To this end, Vero E6 monkey fibroblast cells were chosen for virus production, setting up cell-free and cell-to-cell infection. The 293T/ACE2 cells for this purpose were excluded, as they died quickly after infection with coronavirus, making viral stock generation or maintaining multiple cycles of replication impossible. To remain consistent with pseudoviral tests, the number of plated Vero cells were proportionally similar to what was used for 293T cells. Neutralization of cell-free infection was performed by preincubating 0.01 MOI of SARS-CoV-2 strain hCoV-19/Russia/Moscow_PMV-4 with serially diluted convalescent sera for 1 h, and then adding to the Vero cells, seeded in a 96-well plate overnight. At day five post infection, cytopathic effect (CPE) was measured using the MTT test. As shown in Figure 4A, all sera completely blocked SARS-CoV-2 replication at 1/100 dilution; NT_{50} values ranged from 1/400 to 1/1400. These values were lower than the corresponding NT_{50} determined in the pseudoviral test. This can be explained by the doses of PVs and virions used for the neutralization assays, which are difficult to compare or normalize. Nevertheless, the results of two cell-free assays correlated well to each other (Figure 4B).

Cell-to-cell SARS-CoV-2 spreading assay was initiated by infecting $2.6 \times 10^4$ Vero E6 cells with fully competent virus for 24 h, followed by PBS washing and preincubating with a serum before it was added to 5.6 $\times 10^4$ uninfected Vero E6 cells. The level of CPE was measured five days later using the MTT test. In stark contrast to the cell-free infectious test, the majority of the serum samples, even at minimal dilution, did not prevent the cytopathic effect of fully-competent SARS-CoV-2 (Figure 4C), with the exception of serum 9611, which at 1/20 dilution displayed ~50% inhibitory activity.

In conclusion, it was demonstrated that cell-to-cell spread of the fully competent wild-type SARS-CoV-2 is almost completely resistant to convalescent serum neutralization. This effect was even more pronounced than the resistance detected using PVs.

![Figure 4](image-url)
4. Discussion

The fast and global spread of COVID-19 requires unprecedented efforts to control this pandemic. An important parameter of collective immunity, gained after SARS-CoV-2 infection or vaccination, is the neutralization activity of anti-spike antibodies. This reflects the degree to which the studied population is protected from the infection, and provides more adequate information than a titer of anti-spike antibodies measured by ELISA. However, this test requires strict BSL3 conditions in order to work with highly pathogenic full-length SARS-CoV-2, and it has not been widely utilized. In this respect, different PV systems are considered safe and acceptable for many labs, since they allow the completion of only one cycle of viral replication. The PVs have been adapted by many researchers to characterize the SARS-CoV-2 entry process [3,5,6,23,48,49], monitor the dynamics of neutralizing humoral immunity to SARS-CoV-2 [14,50,51], and screen potential inhibitors [28,37].

The aim of this study was to not just replicate a PV system but rather, develop a lentivirus-based PV test capable of measuring SARS-CoV-2 infection, both with purified PVs and in cell cocultures. The latter has not been appreciated previously or measured accurately. The use of identical vectors to initiate both types of infection makes comparative analysis of PV infectivity more rigorous. First, our system was optimized by pseudotyping PVs with S protein mutants. Since the cytoplasmic portion of the S protein has an ER–Golgi retention signal needed for incorporation into coronaviruses that bud from endosomal membranes [52,53], but which may not be optimal for efficient pseudotyping of lenti- or retroviral particles that assemble predominantly at the plasma membrane, this signal should be removed. An early study on SARS-CoV by Giroglou et al. [43] demonstrated that the C-terminally truncated spike increased PV infectivity, which led to the inclusion of this modification in the many subsequent PV systems developed for SARS-CoV-2 [6,33,45–47,54]. The truncation of the last 18–19 amino acids [45] enhanced PV infectivity from 10- to 100-fold. Consistent with the data reported above, our study has shown that the ΔC19 mutation improved cell-free infection by 15-fold, and one-step infection by 5-fold (Figures 1D and 2B). Nevertheless, a few studies did not find a substantial influence from ΔC19 [46] or point mutations in the ER retention signal [34,56] on PV infectivity. In agreement with published papers [34,43,45], we did not observe substantial differences between wt and ΔC19 S protein levels expressed on the surface of PV producing cells (Figure 1G). Thus, the mechanism of enhanced infectivity for ΔC19 PVs remains unclear, and can be related to improved incorporation of this mutant into PVs [44,45,56] and/or stabilization of S1–S2 subunit interaction [45]. Unlike simple truncation, the substitution of C19 with the most membrane-proximal cytoplasmic domain of gp41, ΔC19-H2 [44], did not alter PV infectivity in our tests. Crawford et al. substituted the cytoplasmic portion of the S protein with the intracellular domain from influenza hemagglutinin, and reported no improvement in PV infectivity as well [34].

Unlike SARS-CoV-1 S, the S protein of SARS-CoV-2 contains a furin cleavage site (F), located a little upstream of the S1/S2 boundary [24]. It became clear early on that the presence of F increases Env-mediated cell–cell fusion, at least for in vitro experiments [23,57]. However, the effects of F on virus infectivity were contradictory, i.e., either a decrease [48] or an increase [49] in ΔF PV infectivity relative to the wt S protein was reported. Finally, several groups found that infectivity depends on the cell target and, in particular, the entry site that the virus uses during infection [2,23,58]. The latter is largely dependent on the S protein cleavage at the S2' site by surface protease TMPRSS2 or lysosomal cathepsins [22]. If cells express TMPRSS2 and the virus enters via the plasma membrane, then ΔF decreased PV infection [23], whereas TMPRSS2-negative target cells, such as the widely used 293T/ACE2 cells, were usually infected similarly [2,23], or even better, with ΔF PVs [48,49,56,58–60], depending on the mutations introduced at the F site. Consistent with these reports, a 15–20-fold increase in infectivity with purified ΔF PVs in 293T/ACE2 cells was detected in this study. Strikingly, one-step transfection/infection using all variants of the S protein with intact F was undetectable (Figure 2B), which was explained by massive syncytia formation.
induced by the S protein (Figure 2C) and by blocking inLuc-mR transduction in fused cells [38]. Thus, measurement of cell coculture infection must adhere to the ΔF variant of spike and be used in cell-free infection for comparative purposes. Summarizing this part of the study, the ΔFAC19 mutant of the S protein was selected as the one providing the highest sensitivity to PV infection, both in cell-free and cell coculture experimental settings. Next, the generated PV system was validated in a neutralization test with convalescent sera. As the ΔF mutation is localized in the external part of the S protein, it can potentially influence serum neutralization activity. A comparison of the ΔFAC19 and ΔC19 mutants revealed that ΔF required ~twofold higher serum concentration for PV neutralization than without ΔF (Figure 3C). This is consistent with the study by Johnson et al. [61], and suggests that using the ΔFAC19 mutant spike slightly underestimated the neutralization potential of sera, but did not overestimate it. Using five selected COVID-19 convalescent sera with high anti-spike titers, inhibitory activity was quantified against the ΔFAC19 in cell-free and cell coculture modes of infection, and NT50 was calculated for all tested sera. It was demonstrated that all convalescent sera were at least tenfold less efficient in the neutralization of cell coculture infection, relative to inhibitory activity detected with purified PVs. This became possible by using a previously developed replication-dependent vector in Luc. There is a limited number of studies in which infectivity or fusogenicity of SARS-CoV-2 PVs was measured using original luciferase-based reporter vectors, such as Gaussia luciferase (Gluc and in-Gluc) [21,47] or split-Nanoluc system [62]. Although the authors of these studies accurately quantified the levels of S-mediated virus–cell and cell–cell fusion, the cell coculture infection per se was not measured. Acknowledging that the validity of the results obtained in this study with lentiviral PVs could be heavily criticized, we conducted neutralization experiments on Vero E6 cells with live full-length SARS-CoV-2, at transmission settings that were as close as possible to those developed for the single-round infection tests. The viral multiple replication assays not only confirmed the results with PVs, but also demonstrated the near complete resistance of SARS-CoV-2 cell coculture infection to neutralizing antibodies (Figure 4C). This phenomenon has been observed for a number of viruses [63–68], but has not been reported for coronaviruses.

Some respiratory viruses have been shown to utilize cell-to-cell transmission. Examples include induction of intercellular extensions by the influenza virus, PV5 [69,70], HMPV [63,71], and RSV [72], and usage of intercellular membrane pores by the measles virus, which is also able to infect airway epithelium [73]. Coronavirus extensively reorganize not only the ER–Golgi network but also change plasma membrane characteristics, inducing formation ruffles and filopodia [74]. Ogando et al. observed that Vero E6 cells infected with SARS-CoV-2 alter their morphology by forming long filopodia with budding viruses [75]. The study on Caco-2 cells by Bouhaddou et al. showed that the N protein of SARS-CoV-2 interacts with the kinase CK2 that leads to cytoskeleton reorganization and filopodia formation [76]. Using scanning electron microscopy, Caldas et al. visualized thin protrusions between Vero cells with adherent virions [77]. Whether the observed intercellular contacts play a role in SARS-CoV-2 cell-to-cell transmission in vivo is not known. Massive cell–cell fusion induced by SARS-CoV-2 has been observed in cell culture [23,57] and in human organoids [78,79], as well as in post-mortem material [80–84]. However, the biological significance of syncytia formation in vivo remains uncertain. The most logical mechanism that would protect SARS-CoV-2 cell-to-cell transmission from antibody neutralization is a tight cellular contact with a synaptic cleft where the virus buds, and where large immunoglobulins may have difficulty penetrating. Our preliminary experiments with much smaller nanobodies that relatively efficiently blocked SARS-CoV-2 cell coculture infection partially support this assumption. This mechanism has been implied for retroviral infectious synapses [85]. However, such structures have not been described for SARS-CoV-2, which transmits in airway epithelium. The neutralizing activity of serum antibodies will also depend on viral inputs used in cell-free and cell coculture infection tests. It cannot be excluded that the continuous production of viral particles and expression of S protein on producer cells during cell-to-cell infection will require more antibodies for
efficient neutralization. Prolonged co-incubation of infected and uninfected Vero cells for 5 days, required for a clear CPE detection, likely leads to virus abundance that somewhat explains the substantially lower neutralization of cell-to-cell infection performed with live coronavirus relative to PVs, which support only a single round of replication.

In conclusion, we developed lentivirus-based single-round pseudoviral infection assays suitable for quantitatively measuring SARS-CoV-2 entry in cell-free and cell coculture conditions. Using this system, as well as the SARS-CoV-2 spreading assay, our study has shown that cell-to-cell infection of SARS-CoV-2 is considerably more resistant to serum neutralization than infection with purified viral particles. These results underline the importance of SARS-CoV-2 cell-to-cell transmission for virus biology, immune protection, and the development of entry inhibitors. Although the developed cell coculture PV system has a serious limitation related to the usage of mutated variants of the spike protein and unnatural core proteins, we believe it will help validate antibodies, peptides, and small molecules that would block virus entry more effectively than inhibitors selected by a conventional PV system.

Author Contributions: Conceptualization, D.M.; methodology, N.K., A.S., and D.M.; validation, N.K., A.S., and D.M.; formal analysis, V.G.; investigation, N.K. and A.S.; data curation, V.G. and D.M.; writing—original draft preparation, N.K.; writing—review and editing, N.K. and D.M.; supervision, D.M. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the grant 075-15-2019-1661 from the Ministry of Science and Higher Education of the Russian Federation.

Institutional Review Board Statement: Study was approved by the local ethics committee of the Moscow First Infectious Disease Hospital (Protocol #2 dated 22 January 2021).

Informed Consent Statement: Informed consent was obtained from all individuals whose serum was tested in the study.

Data Availability Statement: All authors declare that data and materials will be made available according to the guidelines of the journal.

Conflicts of Interest: The authors declare no financial or non-financial interest.

References
1. Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nat. Cell Biol. 2020, 579, 270–273. [CrossRef] [PubMed]

2. Walls, A.C.; Park, Y.-J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Veesler, D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020, 181, 281–292.e6. [CrossRef]

3. Letko, M.; Marzi, A.; Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 2020, 5, 562–569. [CrossRef]

4. Zhu, N.; Wang, W.; Liu, Z.; Liang, C.; Wang, W.; Ye, F.; Huang, B.; Zhao, L.; Wang, H.; Zhou, W.; et al. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. Nat. Commun. 2020, 11, 1–8. [CrossRef]

5. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.-H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271–280.e8. [CrossRef]

6. Ou, X.; Liu, Y.; Lei, X.; Li, P.; Mi, D.; Ren, L.; Guo, L.; Guo, R.; Chen, T.; Hu, J.; et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 2020, 11, 1–12. [CrossRef] [PubMed]

7. Trypsteen, W.; Van Cleemput, J.; Van Snippenberg, W.; Gerlo, S.; Vandekerckhove, L. On the whereabouts of SARS-CoV-2 in the human body: A systematic review. PLOS Pathog. 2020, 16, e1009037. [CrossRef] [PubMed]

8. Müller, J.A.; Groß, R.; Conzelmann, C.; Krüger, J.; Merle, U.; Steinhardt, J.; Weil, T.; Koepke, L.; Bozzo, C.P.; Read, C.; et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat. Metab. 2021, 3, 149–165. [CrossRef]

9. Daly, J.L.; Simonetti, B.; Klein, K.; Chen, K.-E.; Williamson, M.K.; Antón-Plágaro, C.; Shoemark, D.K.; Simón-Gracia, L.; Bauer, M.; Hollandi, R.; et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science 2020, 370, 861–865. [CrossRef]

10. Cantuti-Castelvetri, L.; Ojha, R.; Pedro, L.D.; Djannatian, M.; Franz, J.; Kuivanen, S.; Van Der Meer, F.; Kallio, K.; Kayaa, T.; Anastasina, M.; et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 2020, 370, 856–860. [CrossRef] [PubMed]

11. Wang, S.; Qiu, Z.; Hou, Y.; Deng, X.; Xu, W.; Zheng, T.; Wu, P.; Xie, S.; Bian, W.; Zhang, C.; et al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res. 2021, 31, 126–140. [CrossRef]
12. Wang, K.; Chen, W.; Zhang, Z.; Deng, Y.; Lian, J.-Q.; Du, P.; Wei, D.; Zhang, Y.; Sun, X.-X.; Gong, L.; et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. *Signal Transduct. Target. Ther.* **2020**, *5*, 1–10. [CrossRef] [PubMed]

13. Shilts, J.; Crozier, T.W.M.; Greenwood, E.J.D.; Lehner, P.J.; Wright, G.J. No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. *Sci. Rep.* **2021**, *11*, 1–10. [CrossRef] [PubMed]

14. Hoffmann, M.; Arora, P.; Größ, R.; Seidel, A.; Hörnich, B.F.; Hahn, A.S.; Krüger, N.; Graichen, L.; Hofmann-Winkler, H.; Kempf, A.; et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. *Cell* **2021**. [CrossRef] [PubMed]

15. Rey, F.A.; Lok, S.-M. Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines. *Cell* **2018**, *172*, 1319–1334. [CrossRef] [PubMed]

16. Cohen, F.; Melikyan, G. The Energetics of Membrane Fusion from Binding, through Hemifusion, Pore Formation, and Pore Enlargement. *J. Membr. Biol.* **2004**, *199*, 1–14. [CrossRef] [PubMed]

17. Li, F. Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annu. Rev. Virol.* **2016**, *3*, 237–261. [CrossRef] [PubMed]

18. Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.-L.; Abiona, O.; Graham, B.S.; McLeLLan, J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **2020**, *367*, 1260–1263. [CrossRef] [PubMed]

19. Yao, H.; Song, Y.; Chen, Y.; Wu, N.; Xu, J.; Sun, C.; Zhang, J.; Weng, T.; Zhang, Z.; Wu, Z.; et al. Molecular Architecture of the SARS-CoV-2 Virus. *Cell* **2020**, *183*, 730–738.e13. [CrossRef] [PubMed]

20. Benton, D.J.; Wrobel, A.G.; Xu, P.; Roustan, C.; Martin, S.R.; Rosenthal, P.B.; Skehel, J.J.; Gamblin, S.J. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. *Nat. Cell Biol.* **2020**, *588*, 327–330. [CrossRef] [PubMed]

21. Lu, M.; Uchil, P.D.; Li, W.; Zheng, D.; Terry, D.S.; Gorman, J.; Shi, W.; Zhang, B.; Zhou, T.; Ding, S.; et al. Real-Time Conformational Dynamics of SARS-CoV-2 Spike on Virus Particles. *Cell Host Microbe* **2020**, *28*, 880–891.e8. [CrossRef] [PubMed]

22. Millet, J.K.; Whittaker, G.R. Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. *Virus Res.* **2015**, *202*, 120–132. [CrossRef] [PubMed]

23. Hoffmann, M.; Kleine-Weber, H.; Pöhlmann, S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Cell. Mol. Cell* **2020**, *78*, 779–784.e5. [CrossRef] [PubMed]

24. Andersen, K.G.; Rambaut, A.; Lipkin, W.I.; Holmes, E.C.; Garry, R.F. The proximal origin of SARS-CoV-2. *Nat. Med.* **2020**, *26*, 450–452. [CrossRef] [PubMed]

25. Wu, F.; Wang, A.; Liu, M.; Wang, Q.; Chen, J.; Xia, S.; Ling, Y.; Zhang, Y.; Xun, J.; Lu, L.; et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient and their implications. *medRxiv*. [CrossRef] [PubMed]

26. Chen, X.; Li, R.; Pan, Z.; Qian, C.; Yang, Y.; You, R.; Zhao, J.; Liu, P.; Gao, L.; Li, Z.; et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. *Cell. Mol. Immunol.* **2020**, *17*, 647–649. [CrossRef] [PubMed]

27. Tai, W.; He, L.; Zhang, X.; Pu, J.; Voronin, D.; Jiang, S.; Zhou, Y.; Du, L. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. *Cell. Mol. Immunol.* **2020**, *17*, 613–620. [CrossRef] [PubMed]

28. Lei, C.; Qian, K.; Li, T.; Zhang, S.; Fu, W.; Ding, M.; Hu, S. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. *Nat. Commun.* **2020**, *11*, 1–5. [CrossRef] [PubMed]

29. Xiong, H.-L.; Wu, Y.-T.; Cao, J.-L.; Yang, R.; Liu, Y.-X.; Ma, J.; Qiao, X.-Y.; Yao, X.-Y.; Zhang, B.-H.; Zhang, Y.-L.; et al. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing cell line. *Virus Res.* **2020**, *30*, 343–355. [CrossRef] [PubMed]

30. Pinto, D.; Park, Y.-J.; Beltramello, M.; Walls, A.C.; Tortorici, M.A.; Bianchi, S.; Iaconi, S.; Culap, K.; Zatta, F.; De Marco, A.; et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nat. Cell Biol.* **2020**, *583*, 290–295. [CrossRef] [PubMed]

31. Quinlan, B.D.; Mou, H.; Zhang, L.; Guo, Y.; He, W.; Ojha, A.; Parcells, M.S.; Luo, G.; Li, W.; Zhong, G.; et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. *bioRxiv*. [CrossRef] [PubMed]

32. Nie, J.; Li, Q.; Wu, J.; Zhao, C.; Hao, H.; Liu, H.; Zhang, L.; Nie, L.; Qin, H.; Wang, M.; et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. *Emerg. Microbes Infect.* **2020**, *9*, 680–686. [CrossRef] [PubMed]

33. Xiao, S.; Liu, M.; Wang, C.; Xu, W.; Lan, Q.; Feng, S.; Qi, F.; Bao, L.; Du, L.; Liu, S.; et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Res.* **2020**, *30*, 343–355. [CrossRef] [PubMed]

34. Pinto, D.; Park, Y.-J.; Beltramello, M.; Walls, A.C.; Tortorici, M.A.; Bianchi, S.; Iaconi, S.; Culap, K.; Zatta, F.; De Marco, A.; et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nat. Cell Biol.* **2020**, *583*, 290–295. [CrossRef] [PubMed]

35. Quinlan, B.D.; Mou, H.; Zhang, L.; Guo, Y.; He, W.; Ojha, A.; Parcells, M.S.; Luo, G.; Li, W.; Zhong, G.; et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. *bioRxiv*. [CrossRef] [PubMed]

36. Nie, J.; Li, Q.; Wu, J.; Zhao, C.; Hao, H.; Liu, H.; Zhang, L.; Nie, L.; Qin, H.; Wang, M.; et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. *Emerg. Microbes Infect.* **2020**, *9*, 680–686. [CrossRef] [PubMed]

37. Xiao, S.; Liu, M.; Wang, C.; Xu, W.; Lan, Q.; Feng, S.; Qi, F.; Bao, L.; Du, L.; Liu, S.; et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Res.* **2020**, *30*, 343–355. [CrossRef] [PubMed]

38. Crawford, K.H.D.; Eguia, R.; Dingens, A.S.; Loes, A.N.; Malone, K.D.; Wolf, C.R.; Chu, H.Y.; Tortorici, M.A.; Veesler, D.; Murphy, M.; et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* **2020**, *12*, 513. [CrossRef] [PubMed]

39. Nie, J.; Li, Q.; Wu, J.; Zhao, C.; Hao, H.; Liu, H.; Zhang, L.; Nie, L.; Qin, H.; Wang, M.; et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. *Nat. Protoc.* **2020**, *15*, 3699–3715. [CrossRef] [PubMed]

40. Riepler, L.; Rissler, A.; Falch, A.; Volland, A.; Borena, W.; Von Laer, D.; Kimpel, J. Comparison of Four SARS-CoV-2 Neutralization Assays. *Vaccines* **2020**, *9*, 13. [CrossRef] [PubMed]

41. Zhu, Y.; Yu, D.; Yan, H.; Chong, H.; He, Y. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. *J. Virol.* **2020**, *94*. [CrossRef]
Virtues 2021, 13, 1133

38. Mazurov, D.; Illinskaya, A.; Heidecker, G.; Lloyd, P.; Derse, D. Quantitative Comparison of HTLV-1 and HIV-1 Cell-to-Cell Infection with New Replication Dependent Vectors. PLOS Pathog. 2010, 6, e1000788. [CrossRef]

39. Shunaeva, A.; Potashnikova, D.; Pichugin, A.; Mishina, A.; Filatov, A.; A Nikolaitchik, O.; Hu, W.-S.; Mazurov, D. Improvement of HIV-1 and Human T Cell Lymphotropic Virus Type 1 Replication-Dependent Vectors via Optimization of Reporter Gene Reconstitution and Modification with Intrinsic Short Hairpin RNA. J. Virol. 2015, 89, 10591–10601. [CrossRef] [PubMed]

40. Antipova, N.V.; Larionova, T.D.; Siniavin, A.E.; Nikiforova, M.A.; Gushchin, V.A.; Babichenko, II.; Volkov, A.V.; Shakhparonov, M.I.; Pavlyukov, M.S. Establishment of Murine Hybridoma Cells Producing Antibodies against Spike Protein of SARS-CoV-2. Int. J. Mol. Sci. 2020, 21, 9167. [CrossRef]

41. Amanat, F.; White, K.M.; Miorin, L.; Strohmeier, S.; McMahon, M.; Meade, P.; Liu, W.; Albrecht, R.A.; Simon, V.; Martinez-Sobrido, L.; et al. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Curr. Protoc. Microbiol. 2020, 58, e108. [CrossRef] [PubMed]

42. Siniavin, A.E.; Nikiforova, M.A.; Grinkina, S.D.; Gushchin, V.A.; Starkov, V.G.; Osipov, A.V.; Tsetlin, V.I.; Utkin, Y.N. Snake venom phospholipases A2 possess a strong virucidal activity against SARS-CoV-2 in vitro and block the cell fusion mediated by spike glycoprotein interaction with the ACE2 receptor. bioRxiv 2021. [CrossRef]

43. Giroglou, T.; Cinatl, J.; Rabena, H.; Drosten, C.; Schwalbe, H.; Doerr, H.W.; von Laer, D. Retroviruses Pseudotyped with Severe Acute Respiratory Syndrome Coronavirus S Protein. J. Virol. 2004, 78, 9007–9015. [CrossRef] [PubMed]

44. Moore, M.J.; Dorfman, T.; Suarez, R.; Salcedo, B.; Lepique, M.; Graham, M.; Ricana, C.; Robinson, C.; Ritter, D.G. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. J. Virol. 2020, 94. [CrossRef]

45. Yu, J.; Li, Z.; Gebre, M.S.; Bondzie, E.A.; Wan, H.; Jacob-Dolan, C.; Martinez, D.R.; Nkolola, J.P.; Baric, R.S.; et al. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. J. Virol. 2021, 95. [CrossRef]

46. Neerukonda, S.N.; Vassell, R.; Herrup, R.; Liu, S.; Wang, T.; Takeda, K.; Yang, Y.; Lin, T.-L.; Wang, W.; Weiss, C.D. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLOS ONE 2021, 16, e0248348. [CrossRef]

47. Johnson, M.C.; Lyddon, T.D.; Suarez, R.; Salcedo, B.; Lepique, M.; Graham, M.; Ricana, C.; Robinson, C.; Ritter, D.G. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. J. Virol. 2020, 94. [CrossRef]

48. Shang, J.; Wan, Y.; Luo, C.; Ye, G.; Geng, Q.; Auerbach, A.; Li, F. Cell entry mechanisms of SARS-CoV-2. Proc. Natl. Acad. Sci. USA 2020, 117, 11727–11734. [CrossRef] [PubMed]

49. Zhang, L.; Jackson, C.B.; Mou, H.; Ojha, A.; Peng, H.; Quinlan, B.D.; Rangarajan, E.S.; Pan, A.; Vanderheiden, A.; Suthar, M.S.; et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 2020, 11, 1–9. [CrossRef] [PubMed]

50. Garcia-Beltran, W.F.; Lam, E.C.; Denis, K.S.; Nittido, A.D.; Garcia, Z.H.; Hauser, B.M.; Feldman, J.; Pavlovic, M.N.; Gregory, D.J.; Poznansky, M.C.; et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 2021, 184, 2372–2383.e9. [CrossRef]

51. Dan, J.M.; Mateus, J.; Kato, Y.; Hastie, K.M.; Yu, E.D.; Faliti, C.E.; Grifoni, A.; Ramirez, S.I.; Haupt, S.; Frazier, A.; et al. Immunological memory to SARS-CoV-2 was assessed for up to 8 months after infection. Science 2021, 371, eabf4063. [CrossRef]

52. McBride, C.E.; Li, J.; Machamer, C.E. The Cytoplasmic Tail of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains a Novel Endoplasmic Reticulum Retrieval Signal That Binds COPI and Promotes Interaction with Membrane Protein. J. Virol. 2007, 81, 2418–2428. [CrossRef]

53. V’kovski, P.; Kratzel, A.; Steiner, S.; Stalder, H.; Thiel, V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021, 19, 155–170. [CrossRef] [PubMed]

54. Schmidt, F.; Weisblum, Y.; Muecksch, F.; Hoffmann, H.-H.; Michailidis, E.; Lorenzi, J.C.; Mendoza, P.; Rutkowska, M.; Bednarski, E.; Gaebler, C.; et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 2020, 217. [CrossRef]

55. Fu, X.; Tao, L.; Zhang, X. Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus. Mol. Ther. Methods Clin. Dev. 2021, 20, 350–356. [CrossRef]

56. Nguyen, H.T.; Zhang, S.; Wang, Q.; Anang, S.; Wang, J.; Ding, H.; Kappes, J.C.; Sodroski, J. Spike Glycoprotein and Host Cell Determinants of SARS-CoV-2 Entry and Cytopathic Effects. J. Virol. 2021, 95, 2304–2324. [CrossRef]

57. Xia, S.; Lan, Q.; Su, S.; Wang, X.; Xu, W.; Liu, Z.; Zhu, Y.; Wang, Q.; Lu, L.; Jiang, S. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct. Target. Ther. 2020, 5, 92. [CrossRef]

58. Hansen, J.; Baum, A.; Pascal, K.E.; Russo, V.; Giordano, S.; Wloga, E.; Fulton, B.O.; Yan, Y.; Koon, K.; Patel, K.; et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 2020, 369, 1010–1014. [CrossRef]
60. Zhu, Y.; Feng, F.; Hu, G.; Wang, Y.; Yu, Y.; Zhu, Y.; Xu, W.; Cai, X.; Sun, Z.; Han, W.; et al. The S1/S2 boundary of SARS-CoV-2 spike protein modulates cell entry pathways and transmission. *bioRxiv* 2020. [CrossRef]

61. Johnson, B.A.; Xie, X.; Bailey, A.L.; Kalveram, B.; Lokugamage, K.G.; Murtuza, A.; Zou, J.; Zhang, X.; Juelich, T.; Smith, J.K.; et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. *Nat. Cell Biol.* 2021, 591, 293–299. [CrossRef]

62. Yamamoto, M.; Du, Q.; Song, J.; Wang, H.; Watanabe, A.; Tanaka, Y.; Kawaguchi, Y.; Inoue, J.-I.; Matsuda, Z. Cell–cell and virus–cell fusion assay–based analyses of alanine insertion mutants in the distal α9 portion of the JRFL gp41 subunit from HIV-1. *J. Biol. Chem.* 2019, 294, 5677–5687. [CrossRef]

63. El Najjar, F.; Cifuentes-Muñoz, N.; Chen, J.; Zhu, H.; Buchholz, U.J.; Moncman, C.L.; Dutch, R.E. Human metapneumovirus induces reorganization of the actin cytoskeleton for direct cell-to-cell spread. *PLOS Pathog.* 2016, 12, e1005922. [CrossRef]

64. Brimacombe, C.L.; Grove, J.; Meredith, L.W.; Hu, K.; Syder, A.J.; Flores, M.V.; Timpe, J.M.; Krieger, S.E.; Baumert, T.F.; Tellinghuisen, T.L.; et al. Neutralizing Antibody-Resistant Hepatitis C Virus Cell-to-Cell Transmission. *J. Virol.* 2010, 85, 596–605. [CrossRef]

65. Martin, N.; Welsch, S.; Jolly, C.; Briggs, J.A.G.; Vaux, D.; Sattentau, Q.J. Virological Synapse-Mediated Spread of Human Immunodeficiency Virus Type 1 between T Cells Is Sensitive to Entry Inhibition. *J. Virol.* 2010, 84, 3516–3527. [CrossRef]

66. Merwaiss, F.; Cziipener, C.; Alvarez, D.E. Cell-to-Cell Transmission Is the Main Mechanism Supporting Bovine Viral Diarrhea Virus Spread in Cell Culture. *J. Virol.* 2018, 93. [CrossRef]

67. Xiao, F.; Fofana, I.; Heydmann, L.; Barth, H.; Soulier, E.; Habersetzer, F.; Doffoël, M.; Buhk, J.; Patel, A.H.; Zeisel, M.B.; et al. Hepatitis C Virus Cell-to-Cell Transmission and Resistance to Direct-Acting Antiviral Agents. *PLOS Pathog.* 2014, 10, e1004128. [CrossRef]

68. Mothes, W.; Sherer, N.M.; Jin, J.; Zhong, P. Virus Cell-to-Cell Transmission. *J. Virol.* 2010, 84, 8360–8368. [CrossRef]

69. Roberts, K.L.; Manicassamy, B.; Lamb, R.A. Influenza A Virus Uses Intercellular Connections To Spread to Neighboring Cells. *J. Virol.* 2015, 89, 1537–1549. [CrossRef]

70. Kumar, A.; Kim, J.H.; Ranjan, P.; Metcalfe, M.G.; Cao, W.; Mishina, M.; Gangappa, S.; Guo, Z.; Boyden, E.S.; Zaki, S.; et al. Influenza virus exploits tunneling nanotubes for cell-to-cell spread. *Sci. Rep.* 2017, 7, 40360. [CrossRef]

71. Kinder, J.T.; Moncman, C.L.; Barrett, C.; Jin, H.; Kallewaard, N.; Dutch, R.E. Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies. *J. Virol.* 2020, 94. [CrossRef]

72. Mehedi, M.; McCarty, T.; Martin, S.E.; Le Nouën, C.; Buehler, E.; Chen, Y.-C.; Smelkinson, M.; Buhk, J.; Patel, A.H.; Zeisel, M.B.; et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. *J. Virol.* 2020, 10, e1006062. [CrossRef]

73. Singh, B.; Hornick, A.L.; Krishnamurthy, S.; Locke, A.C.; Mendoza, C.A.; Mateo, M.; Miller-Hunt, C.L.; Cattaneo, R.; Sinn, P.L. The Nectin-4/Afadin Protein Complex and Intercellular Membrane Pores Contribute to Rapid Spread of Measles Virus in Primary Human Airway Epithelia. *J. Virol.* 2015, 89, 7089–7096. [CrossRef]

74. Ng, M.; Lee, J.; Leong, M.; Ling, A.-E.; Tan, H.-C.; Ooi, E. Topographic Changes in SARS Coronavirus–infected Cells at Late Stages of Infection. *Emerg. Infect. Dis.* 2004, 10, 1907–1914. [CrossRef]

75. Ogando, N.S.; Dalebout, T.J.; Zevenhoven-Dobbe, J.C.; Limpens, R.W.; Van Der Meer, Y.; Caly, L.; Druce, J.; De Vries, J.J.C.; Kikker, M.; Bärzca, M.; et al. SARS-coronavirus-2 replication in Vero E6 cells: Replication kinetics, rapid adaptation and cytopathology. *J. Gen. Virol.* 2020, 101, 925–940. [CrossRef] [PubMed]

76. Bouhadou, M.; Memon, D.; Meyer, B.; White, K.M.; Rezelj, V.V.; Marrero, M.C.; Polacco, B.J.; Melnyk, J.E.; Ulfters, S.; Kaake, R.M.; et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. *Cell 2020*, 182, 685–712.e19. [CrossRef]

77. Balasubramanian, S.; Mota, M.A.; Castro, B.T.; Zhao, X.; Zhong, H.; Meng, Q.; Zhao, X.; Li, H.; Qin, H.; et al. Ultrastructural analysis of SARS-CoV-2 interactions with the host cell via high resolution scanning electron microscopy. *Sci. Rep.* 2020, 10, 1–8. [CrossRef]

78. Zang, R.; Castro, M.F.G.; McCune, B.T.; Zeng, Q.; Rothlauf, P.W.; Sonnek, N.M.; Liu, Z.; Brulois, K.F.; Wang, X.; Greenberg, H.B.; et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. *Sci. Immunol.* 2020, 5, eabc3582. [CrossRef]

79. Mykytyn, A.Z.; Bruegem, T.; Rieseboch, S.; Schipper, D.; Doel, P.B.V.D.; Rottier, R.J.; Lamers, M.M.; Haagmans, B.L. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site. *elife 2021*, 10, 1–23. [CrossRef]

80. Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir. Med.* 2020, 8, 420–422. [CrossRef]

81. Bussani, R.; Schneider, E.; Zentilin, L.; Collesi, C.; Ali, H.; Braga, L.; Volpe, M.C.; Colliva, A.; Zanconati, F.; Berlot, G.; et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. *EBioMedicine* 2020, 61. [CrossRef] [PubMed]

82. Sanders, D.W.; Jumper, C.C.; Ackerman, P.J.; Bracha, D.; Donlic, A.; Kim, H.; Kenney, D.; Castello-Serrano, I.; Suzuki, S.; Tamura, T.; et al. SARS-CoV-2 requires cholesterol for viral entry and pathological syncytium formation. *elife 2020*, e65962. [CrossRef]
83. Bryce, C.; Grimes, Z.; Pujadas, E.; Ahuja, S.; Beth Beasley, M.; Albrecht, R.; Hernandez, T.; Stock, A.; Zhao, Z.; Al Rasheed, M.; et al. Pathophysiology of SARS-CoV-2: Targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. *medRxiv* 2020. [CrossRef]

84. Rockx, B.; Kuiken, T.; Herfst, S.; Bestebroer, T.; Lamers, M.M.; Munnink, B.B.O.; De Meulder, D.; Van Amerongen, G.; Brand, J.V.D.; Okba, N.M.A.; et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. *Science* 2020, 368, 1012-1015. [CrossRef] [PubMed]

85. Dufloo, J.; Bruel, T.; Schwartz, O. HIV-1 cell-to-cell transmission and broadly neutralizing antibodies. *Retrovirology* 2018, 15, 1-14. [CrossRef]